SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-024964
Filing Date
2021-05-06
Accepted
2021-05-06 16:10:32
Documents
14
Period of Report
2021-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K-050621 Q1-21 EARNINGS ctmx-8k_20210506.htm   iXBRL 8-K 39081
2 EX-99.1 - Q1-21 EARNINGS ctmx-ex991_47.htm EX-99.1 255328
3 GRAPHIC gsrv1jo4kyno000001.jpg GRAPHIC 32063
  Complete submission text file 0001564590-21-024964.txt   488470

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20210506.xsd EX-101.SCH 5752
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20210506_lab.xml EX-101.LAB 20236
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20210506_pre.xml EX-101.PRE 12073
7 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-8k_20210506_htm.xml XML 3702
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 21897834
SIC: 2834 Pharmaceutical Preparations